These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 8495427

  • 21. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M.
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pathogenesis of ascites in mice with peritoneal carcinomatosis.
    Fastaia J, Dumont AE.
    J Natl Cancer Inst; 1976 Mar; 56(3):547-50. PubMed ID: 1255784
    [Abstract] [Full Text] [Related]

  • 24. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.
    De Cesare M, Sfondrini L, Campiglio M, Sommariva M, Bianchi F, Perego P, van Rooijen N, Supino R, Rumio C, Zunino F, Pratesi G, Tagliabue E, Balsari A.
    J Immunother; 2010 Jan; 33(1):8-15. PubMed ID: 19952960
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
    Horton HM, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE.
    J Immunol; 1999 Dec 15; 163(12):6378-85. PubMed ID: 10586027
    [Abstract] [Full Text] [Related]

  • 27. Pathways for fluid loss from the peritoneal cavity.
    Shockley TR, Ofsthun NJ.
    Blood Purif; 1992 Dec 15; 10(3-4):115-21. PubMed ID: 1308677
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
    Pourgholami MH, Yan Cai Z, Lu Y, Wang L, Morris DL.
    Clin Cancer Res; 2006 Mar 15; 12(6):1928-35. PubMed ID: 16551879
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Lymphatic drainage of the peritoneal cavity in sheep.
    Abernethy NJ, Chin W, Hay JB, Rodela H, Oreopoulos D, Johnston MG.
    Am J Physiol; 1991 Mar 15; 260(3 Pt 2):F353-8. PubMed ID: 2000952
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells.
    Yeo TK, Nagy JA, Yeo KT, Dvorak HF, Toole BP.
    Am J Pathol; 1996 Jun 15; 148(6):1733-40. PubMed ID: 8669459
    [Abstract] [Full Text] [Related]

  • 37. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity.
    Zhu GG, Risteli J, Puistola U, Kauppila A, Risteli L.
    Cancer Res; 1993 Oct 15; 53(20):5028-32. PubMed ID: 8402695
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.